# Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

> **NCT01978093** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 600 (actual)

## Conditions studied

- Neisseria Meningitidis
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** Hib-MenCY-TT (MenHibrix®)
- **BIOLOGICAL:** Pediarix®
- **BIOLOGICAL:** Rotarix®
- **BIOLOGICAL:** Prevnar 13®
- **BIOLOGICAL:** PedvaxHIB®
- **BIOLOGICAL:** Havrix®

## Key facts

- **NCT ID:** NCT01978093
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-01
- **Primary completion:** 2016-03-18
- **Final completion:** 2016-03-18
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01978093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01978093, "Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01978093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*